Fidelity Investments
RLAY icon

Fidelity Investments’s Relay Therapeutics RLAY Stock Holding History

Fidelity Investments’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376M Buy
20,110,113
+16,414,682
+444% +$238M 0.02% 665
2026
Q1 		$36.8M Buy
3,695,431
+3,533,209
+2,178% +$31.6M ﹤0.01% 1541
2025
Q4 		$1.37M Sell
162,222
-520
-0.3% -$3.71K ﹤0.01% 2737
2025
Q3 		$850K Buy
162,742
+4,563
+3% +$17.4K ﹤0.01% 2847
2025
Q2 		$547K Buy
158,179
+115,164
+268% +$343K ﹤0.01% 2929
2025
Q1 		$113K Sell
43,015
-53,667
-56% -$210K ﹤0.01% 3503
2024
Q4 		$398K Buy
96,682
+6,910
+8% +$37.6K ﹤0.01% 3013
2024
Q3 		$636K Buy
89,772
+19,296
+27% +$144K ﹤0.01% 2758
2024
Q2 		$460K Sell
70,476
-1,015,613
-94% -$6.94M ﹤0.01% 2765
2024
Q1 		$9.01M Sell
1,086,089
-368,854
-25% -$3.6M ﹤0.01% 1902
2023
Q4 		$16M Sell
1,454,943
-652,790
-31% -$5.51M ﹤0.01% 1700
2023
Q3 		$17.7M Sell
2,107,733
-848,488
-29% -$9.12M ﹤0.01% 1631
2023
Q2 		$37.1M Sell
2,956,221
-5,850,770
-66% -$72.8M ﹤0.01% 1381
2023
Q1 		$145M Sell
8,806,991
-926,857
-10% -$16.6M 0.01% 851
2022
Q4 		$145M Sell
9,733,848
-2,224,364
-19% -$42.6M 0.01% 819
2022
Q3 		$268M Sell
11,958,212
-1,376,843
-10% -$30.2M 0.03% 568
2022
Q2 		$223M Sell
13,335,055
-2,906,951
-18% -$62.3M 0.02% 647
2022
Q1 		$486M Buy
16,242,006
+35,405
+0.2% +$859K 0.04% 450
2021
Q4 		$498M Buy
16,206,601
+2,519,797
+18% +$79.6M 0.04% 457
2021
Q3 		$432M Buy
13,686,804
+3,324,804
+32% +$112M 0.03% 487
2021
Q2 		$379M Buy
10,362,000
+4,533,548
+78% +$149M 0.03% 548
2021
Q1 		$201M Buy
5,828,452
+1,066,214
+22% +$46.3M 0.02% 785
2020
Q4 		$198M Sell
4,762,238
-53,641
-1% -$2.42M 0.02% 750
2020
Q3 		$205M Buy
+4,815,879
New +$184M 0.02% 627

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Fidelity Investments's RLAY Position: Q2 2026 in Review

Fidelity Investments increased its Relay Therapeutics (RLAY) stake by 444% in Q2 2026, buying an estimated $238M and bringing the position to 20,110,113 shares worth $376M. The position accounts for 0.02% of the portfolio, ranked #665.

Fidelity Investments first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. The position peaked at $498M in Q4 2021. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Fidelity Investments held 20,110,113 shares of Relay Therapeutics worth $376M as of Q2 2026.
  • Fidelity Investments bought 16,414,682 Relay Therapeutics shares in Q2 2026, an estimated $238M.
  • Relay Therapeutics made up 0.02% of Fidelity Investments's portfolio in Q2 2026, its #665 holding.
  • Fidelity Investments first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Fidelity Investments's Relay Therapeutics position peaked at $498M in Q4 2021.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.